Evening Primrose Oil.

The gamma-linolenic acid in evening primrose oil is a polyunsaturated fatty acid that oxidizes on exposure to air, heat and light. Tocopherol is the chain-breaking antioxidant paired with it to keep the oil intact.

GLA elongates to dihomo-gamma-linolenic acid, which delta-5 desaturase can push onward to arachidonic acid. EPA competes at that same enzyme, so co-dosing tends to hold more of the pool at the DGLA step.

Delta-6 desaturase activity on omega-6 fatty acids depends on zinc status, and low zinc slows that conversion. The pairing is long-standing formulation practice for keeping the pathway that uses GLA running normally.

Both oils are used for gamma-linolenic acid, with borage carrying roughly three times the concentration evening primrose does. They are combined or substituted to reach a target GLA dose from a broader fatty acid base.

Pyridoxine contributes to delta-6 desaturase activity, the step that converts linoleic acid to the gamma-linolenic acid this oil delivers ready-made. Formulas for cyclical support have paired the two for decades.

Magnesium is required for delta-6 desaturase and for the elongation steps that carry gamma-linolenic acid on to dihomo-gamma-linolenic acid. It supports the conversion that determines what the oil becomes in the body.

Alpha-linolenic acid from flax and linoleic acid both compete for the same delta-6 desaturase, and a large ALA dose slows the omega-6 branch. Stacking the two oils shifts the balance rather than adding to it.

Gamma-linolenic acid feeds the series-1 prostaglandin route that reduces platelet aggregation, and ginkgolides antagonise platelet activating factor. The two effects on normal clotting add.

Chasteberry acts on dopaminergic control of prolactin release while the oil acts through prostaglandin balance. Formulas for cyclical female support combine the hormonal and the eicosanoid lever.

Black cohosh triterpene glycosides act on serotonergic and estrogen-receptor signalling, a different route from prostaglandin balance. Products for women through the midlife hormonal shift routinely pair them.

A polyunsaturated seed oil oxidises in the capsule, and rosemary diterpenes are a standard in-oil antioxidant used to slow that. This is bottle-side protection of the ingredient.

Ascorbate regenerates oxidised vitamin E at the interface between oil and water, and vitamin E is what protects the oil's double bonds. Supplying both keeps that recycling loop running.

Gingerols act on thromboxane synthase while gamma-linolenic acid feeds a prostaglandin route that lowers platelet aggregation. Together the effect on normal platelet function is larger than either alone.

Linoleic acid is the substrate delta-6 desaturase converts into gamma-linolenic acid, and a high background intake of linoleic acid occupies that enzyme. Evening primrose oil supplies preformed GLA and so steps past the bottleneck, but the two still share downstream elongation and desaturation capacity. Flagged as competitive so a formulator does not read the two as simply additive.

GLA from evening primrose oil elongates to dihomo-gamma-linolenic acid, which competes with arachidonic acid for cyclooxygenase. EPA competes at the same enzymes from the omega-3 side and also restrains the conversion of DGLA onward to arachidonic acid. Combining them shifts the substrate mix at one shared enzyme system rather than adding two separate effects.

DHA and the fatty acids from evening primrose oil are both incorporated into membrane phospholipids, drawing on the same acyltransferase capacity. Raising one changes the proportional space available to the other. This is compositional chemistry, described here without any claim about a clinical result.

Polyunsaturated fatty acids are the preferred target of lipid peroxidation, and the selenium-dependent glutathione peroxidases are what reduce lipid hydroperoxides once they form. Adding polyunsaturated oil without adequate selenium status leaves that clean-up step limited. The relationship is enzymology, not a combination trial.

Evening primrose oil is a triglyceride and has to be hydrolysed by pancreatic lipase before its fatty acids can be taken up. Where lipase output is low, more of the oil passes through unabsorbed. Supplemental lipase addresses the hydrolysis step only, and does nothing to the fatty acid profile itself.

Fatty acids released by lipase have to be carried into mixed micelles by bile salts before crossing the enterocyte membrane. People with reduced bile flow absorb less from any oil, including this one. Ox bile addresses the solubilisation step, which is why it appears in fat-forward formulas.

Phospholipid emulsifiers disperse an oil into finer droplets, which increases the surface area available to lipase. This is a delivery consideration rather than a biochemical partnership. Effect on absorption is plausible from surface chemistry and not quantified here.

Astaxanthin partitions into the lipid phase where polyunsaturated fatty acids oxidise, the same compartment tocopherols occupy. Formulators pair carotenoid and tocopherol antioxidants with polyunsaturated oils on that basis. No combination measurement supports it, hence Early.

Safflower oil is dominated by linoleic acid and carries no gamma-linolenic acid, which is why it is often the comparator arm in evening primrose oil trials. Taken together, it adds substrate pressure at delta-6 desaturase without contributing GLA. Worth flagging for anyone reading a trial where safflower oil was the control.

Tocopherols interrupt the radical chain reaction that turns a polyunsaturated oil rancid, which is why they are standard in evening primrose softgels. The role is protecting the oil in the capsule as much as anything systemic. Stated here as oil chemistry, not as an added physiological effect.